The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Research Report 2025
Synopsis
The global ESR1 Mutated Metastatic Breast Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for ESR1 Mutated Metastatic Breast Cancer Diagnostics in Hospital Associated Labs is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of ESR1 Mutated Metastatic Breast Cancer Diagnostics include APIS Assay Technologies, lllumina, Inc., GENCURIX, RainSure Scientific, NeoGenomics Laboratories, Sysmex Corporation, ASURAGEN,INC and Guardant Health, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for ESR1 Mutated Metastatic Breast Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ESR1 Mutated Metastatic Breast Cancer Diagnostics.
Report Scope
The ESR1 Mutated Metastatic Breast Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ESR1 Mutated Metastatic Breast Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
APIS Assay Technologies
lllumina, Inc.
GENCURIX
RainSure Scientific
NeoGenomics Laboratories
Sysmex Corporation
ASURAGEN,INC
Guardant Health
Segment by Type
NGS Based
PCR Based
Segment by Application
Hospital Associated Labs
lndependent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research lnstitutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ESR1 Mutated Metastatic Breast Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global ESR1 Mutated Metastatic Breast Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for ESR1 Mutated Metastatic Breast Cancer Diagnostics in Hospital Associated Labs is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of ESR1 Mutated Metastatic Breast Cancer Diagnostics include APIS Assay Technologies, lllumina, Inc., GENCURIX, RainSure Scientific, NeoGenomics Laboratories, Sysmex Corporation, ASURAGEN,INC and Guardant Health, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for ESR1 Mutated Metastatic Breast Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ESR1 Mutated Metastatic Breast Cancer Diagnostics.
Report Scope
The ESR1 Mutated Metastatic Breast Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ESR1 Mutated Metastatic Breast Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
APIS Assay Technologies
lllumina, Inc.
GENCURIX
RainSure Scientific
NeoGenomics Laboratories
Sysmex Corporation
ASURAGEN,INC
Guardant Health
Segment by Type
NGS Based
PCR Based
Segment by Application
Hospital Associated Labs
lndependent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research lnstitutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ESR1 Mutated Metastatic Breast Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 NGS Based
1.2.3 PCR Based
1.3 Market by Application
1.3.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Associated Labs
1.3.3 lndependent Diagnostic Laboratories
1.3.4 Diagnostic Imaging Centers
1.3.5 Cancer Research lnstitutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Perspective (2019-2030)
2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Growth Trends by Region
2.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Dynamics
2.3.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Trends
2.3.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Drivers
2.3.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Challenges
2.3.4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Players by Revenue
3.1.1 Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue
3.4 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Concentration Ratio
3.4.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue in 2023
3.5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into ESR1 Mutated Metastatic Breast Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Breakdown Data by Type
4.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Breakdown Data by Application
5.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
6.2 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
7.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 APIS Assay Technologies
11.1.1 APIS Assay Technologies Company Detail
11.1.2 APIS Assay Technologies Business Overview
11.1.3 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.1.4 APIS Assay Technologies Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.1.5 APIS Assay Technologies Recent Development
11.2 lllumina, Inc.
11.2.1 lllumina, Inc. Company Detail
11.2.2 lllumina, Inc. Business Overview
11.2.3 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.2.4 lllumina, Inc. Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.2.5 lllumina, Inc. Recent Development
11.3 GENCURIX
11.3.1 GENCURIX Company Detail
11.3.2 GENCURIX Business Overview
11.3.3 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.3.4 GENCURIX Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.3.5 GENCURIX Recent Development
11.4 RainSure Scientific
11.4.1 RainSure Scientific Company Detail
11.4.2 RainSure Scientific Business Overview
11.4.3 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.4.4 RainSure Scientific Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.4.5 RainSure Scientific Recent Development
11.5 NeoGenomics Laboratories
11.5.1 NeoGenomics Laboratories Company Detail
11.5.2 NeoGenomics Laboratories Business Overview
11.5.3 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.5.4 NeoGenomics Laboratories Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.5.5 NeoGenomics Laboratories Recent Development
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Detail
11.6.2 Sysmex Corporation Business Overview
11.6.3 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.6.4 Sysmex Corporation Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.6.5 Sysmex Corporation Recent Development
11.7 ASURAGEN,INC
11.7.1 ASURAGEN,INC Company Detail
11.7.2 ASURAGEN,INC Business Overview
11.7.3 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.7.4 ASURAGEN,INC Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.7.5 ASURAGEN,INC Recent Development
11.8 Guardant Health
11.8.1 Guardant Health Company Detail
11.8.2 Guardant Health Business Overview
11.8.3 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.8.4 Guardant Health Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.8.5 Guardant Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
